Israel-Based Company Uses a Placenta-based Cell-therapy Product to Cure Fatal COVID-19 Cases

An Israel-based regenerative medicine company named Pluristem Therapeutics has finished giving treatment to its first three COVID-19 patients using a placenta-base cell-therapy product, says a recent article from The Jerusalem Post.


According to the CEO and president of the company Yaky Yanay, they were honored to take part in the efforts of the world to provide support to patients and healthcare systems.

The company was reported to have given COVID-19 patients from two different hospitals in Israel. The program to treat COVID-19 patients was approved by the country’s Health Ministry.

The company aims to enroll additional COVID-19 patients in Israel for the coming days. It will be giving updates on significant data and outcomes, says the company.


The patients who received the treatment are high risk. It means that they were older and have pre-existing health conditions. Also, the patients were intubated with a mechanical ventilator.

Pluristem Therapeutics is carefully monitoring the
condition of the patients alongside medical personnel taking care of them.

The PLX cells of Pluristem Therapeutics can induce the natural regulatory T-cells and M2 macrophages of the patient’s immune system. The result of the treatment is the reversal of the overreaction of the patient’s immune system. This has the chance of reducing the fatal symptoms of COVID-19 such as pneumonitis and pneumonia.

Basing on the previous preclinical discoveries involving PLX cells, it is revealed that it has a relevant therapeutic effect in animal studies involving lung fibrosis, acute kidney injury, gastrointestinal injury, and pulmonary hypertension.

Currently, the company is in the process of conversing with the United States and Europe regulators to “define” the company’s strategy against COVID-19.
The advanced capabilities of Pluristem allow the company to help support the needs of treating a huge number of patients in different parts of the world. The company commits to helping provide a solution to the current global crisis brought by the COVID-19 pandemic.